|Seth A. Rudnick, M.D.|
Seth A. Rudnick serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc., and served in this role with the company’s predecessor, POZEN Inc., since July of 2011. He is a member of the audit and governance/nominating committees. Dr. Rudnick is retired from Canaan Partners, where he built the global venture capital firm’s capability in biopharmaceutical investing. He has led many drug discovery and development projects throughout his career in the pharmaceutical and biotech industries, which spans research, development, clinical trials analysis and biotechnology as well as founding and growing start-up companies. Prior to joining Canaan Partners, Dr. Rudnick served as Chief Executive Officer and Chairman of CytoTherapeutics, a company developing stem cell-based therapies to combat chronic diseases. He also helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson that provides life-improving products to individuals with a focus on cancer and chronic illnesses. He is currently a Clinical Adjunct Professor of Medicine at University of North Carolina, Chapel Hill, teaching and advising faculty members on biotechnology issues. Dr. Rudnick also serves on the Board of Directors for Liquidia and G1 Therapeutics.